Unger-Saldaña Karla
Karla Unger-Saldaña, Economy Division, Centro de Investigación y Docencia Económicas (CIDE), 01210 Mexico City, México.
World J Clin Oncol. 2014 Aug 10;5(3):465-77. doi: 10.5306/wjco.v5.i3.465.
This critical review of the literature assembles and compares available data on breast cancer clinical stage, time intervals to care, and access barriers in different countries. It provides evidence that while more than 70% of breast cancer patients in most high-income countries are diagnosed in stages I and II, only 20%-50% patients in the majority of low- and middle-income countries are diagnosed in these earlier stages. Most studies in the developed world show an association between an advanced clinical stage of breast cancer and delays greater than three months between symptom discovery and treatment start. The evidence assembled in this review shows that the median of this interval is 30-48 d in high-income countries but 3-8 mo in low- and middle-income countries. The longest delays occur between the first medical consultation and the beginning of treatment, known as the provider interval. The little available evidence suggests that access barriers and quality deficiencies in cancer care are determinants of provider delay in low- and middle-income countries. Research on specific access barriers and deficiencies in quality of care for the early diagnosis and treatment of breast cancer is practically non-existent in these countries, where it is the most needed for the design of cost-effective public policies that strengthen health systems to tackle this expensive and deadly disease.
这篇文献综述汇集并比较了不同国家乳腺癌临床分期、获得治疗的时间间隔以及就医障碍等方面的现有数据。它提供的证据表明,在大多数高收入国家,超过70%的乳腺癌患者在I期和II期被诊断出来,而在大多数低收入和中等收入国家,只有20%-50%的患者在这些早期阶段被诊断出来。发达国家的大多数研究表明,乳腺癌临床分期较晚与症状发现和开始治疗之间延迟超过三个月有关。本综述汇总的证据显示,在高收入国家,这一间隔的中位数为30-48天,但在低收入和中等收入国家为3-8个月。最长的延迟发生在首次就医咨询和开始治疗之间,即所谓的医疗服务间隔。现有少量证据表明,低收入和中等收入国家癌症治疗中的就医障碍和质量缺陷是造成医疗服务间隔延迟的决定因素。在这些国家,对于乳腺癌早期诊断和治疗的具体就医障碍和护理质量缺陷的研究几乎不存在,而在这些国家,为加强卫生系统以应对这种昂贵且致命的疾病而设计具有成本效益的公共政策时,这种研究最为迫切需要。